A

t least three states have recently introduced bills to require transparency surrounding the cost and pricing of diabetes medicines, posing a growing challenge to the pharmaceutical industry.

Over the past few weeks, legislation was introduced in South Carolina, Hawaii, and Colorado, and the intent of each bill largely mirrors a controversial law that was adopted last fall by Nevada, which is now fending off a lawsuit filed by the industry’s largest trade group.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy